Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Q4 and near-term CDMO volume growth expected to remain strong with double-digit growth visible in Q4. The company expects steady volume growth to continue, with Q4 also showing strong double-digit volume traction, indicating near-term sustainability.
From Akums Drugs & Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Q4 and near-term CDMO volume growth expected to remain strong with double-digit growth visible in Q4.
- FY '26: Zambia contract supplies expected to generate $25 million revenue in H1, with similar revenue expected in FY '27.
- FY '27 capex to continue in line with past trends, focused on capacity expansion to meet growing dosage form needs.
- European CDMO contract: Annual opportunity estimated at EUR35 million, with commercial supplies slated to start in FY '27 after registration in Europe.
- Domestic business volumes expected to align with industry growth from next fiscal year, after minimal price increases and HQ rationalizations.
- Management aiming for breakeven and turnaround in API business through portfolio diversification and entering regulated markets.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has made a total capital expenditure (capex) of INR 165 crores in the first 9 months, with INR 57 crores invested in the latest quarter.
- Capex investments will continue steadily, aligned with business requirements, maintenance, and modernization efforts, following past trends.
- Buffer capacity is maintained to handle increased demand and sudden growth; peak capacity utilization is around 55-60%.
- Future capex will focus on serving dosage forms where current capacities are stretched.
- The company is actively evaluating multiple strategic acquisitions to complement existing business, but no binding deals yet.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The European contract orderbook is significant, with discussions indicating an opportunity of approximately EUR 35 million annually.
- The supply of finished oral formulations from Plant 1 to Europe has already commenced in the current fiscal year.
- Injectable facilities and other plants are still ramping up, with utilization currently low (in the teens) and revenue contribution minimal, expected to increase notably in Q2 and Q3 of the next financial year.
2 more points management made on order book & pipeline
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q3 FY26 results?
Q4 and near-term CDMO volume growth expected to remain strong with double-digit growth visible in Q4. The company expects steady volume growth to continue, with Q4 also showing strong double-digit volume traction, indicating near-term sustainability.
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
The company has made a total capital expenditure (capex) of INR 165 crores in the first 9 months, with INR 57 crores invested in the latest quarter.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.